Aurisco Pharmaceutical Co.,Ltd.
SSE:605116.SS
21.07 (CNY) • At close June 6, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2025 Q1 | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | 2019 Q4 | 2019 Q3 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 401.995 | 387.419 | 355.939 | 394.01 | 335.623 | 340.002 | 369.879 | 250.514 | 302.136 | 239.118 | 260.021 | 290.104 | 218.833 | 214.278 | 187.311 | 215.446 | 186.328 | 177.851 | 160.908 | 201.967 | 180.713 | 144.118 | 150.508 |
| Cost of Revenue
| 157.849 | 156.866 | 140.629 | 165.909 | 155.458 | 147.314 | 131.775 | 112.986 | 164.483 | 101.421 | 139.241 | 149.978 | 97.036 | 108.761 | 83.507 | 109.764 | 106.613 | 112.447 | 76.701 | 101.558 | 89.831 | 61.763 | 72.775 |
| Gross Profit
| 244.146 | 230.552 | 215.31 | 228.101 | 180.165 | 192.688 | 238.103 | 137.528 | 137.653 | 137.697 | 120.78 | 140.125 | 121.798 | 105.516 | 103.804 | 105.683 | 79.715 | 65.404 | 84.208 | 100.409 | 90.883 | 82.355 | 77.734 |
| Gross Profit Ratio
| 0.607 | 0.595 | 0.605 | 0.579 | 0.537 | 0.567 | 0.644 | 0.549 | 0.456 | 0.576 | 0.464 | 0.483 | 0.557 | 0.492 | 0.554 | 0.491 | 0.428 | 0.368 | 0.523 | 0.497 | 0.503 | 0.571 | 0.516 |
| Reseach & Development Expenses
| 32.087 | 40.97 | 39.93 | 33.39 | 28.932 | 41.101 | 39.872 | 30.196 | 25.717 | 36.073 | 25.69 | 23.318 | 32.182 | 28.537 | 12.85 | 16.316 | 11.648 | 16.397 | 9.449 | 11.564 | 9.944 | 17.761 | 5.039 |
| General & Administrative Expenses
| 40.866 | -51.787 | 89.332 | -5.979 | 37.342 | -50.07 | 84.759 | -1.32 | 37.864 | -36.677 | 68.479 | -10.493 | 28.877 | -32.515 | 58.065 | -8.042 | 23.846 | -30.512 | 22.662 | -7.913 | 16.527 | -28.857 | 22.516 |
| Selling & Marketing Expenses
| 29.214 | 8.692 | 34.281 | 44.852 | 24.129 | 33.535 | 41.38 | 15.13 | 10.732 | 11.239 | 9.048 | 10.312 | 9.264 | 8.013 | 7.219 | 7.928 | 6.54 | -3.819 | 5.196 | 9.29 | 10.68 | 11.759 | 4.793 |
| SG&A
| 70.08 | -43.094 | 123.613 | 86.406 | 61.472 | -16.535 | 126.139 | 13.81 | 48.596 | -25.438 | 77.526 | -0.181 | 38.141 | -24.503 | 65.285 | -0.114 | 30.385 | -34.331 | 27.859 | 1.376 | 27.206 | -17.098 | 27.31 |
| Other Expenses
| 0.44 | 148.254 | -55.01 | 0.138 | -1.341 | -1.116 | 1.939 | -2.241 | -0.591 | 86.93 | -35.659 | 35.673 | -2.209 | -0.161 | -1.085 | -0.106 | -0.257 | 0.06 | -0.102 | -1.095 | -0.396 | 37.275 | -1.673 |
| Operating Expenses
| 102.608 | 146.13 | 108.534 | 119.796 | 92.145 | 124.863 | 120.575 | 90.192 | 73.722 | 97.566 | 67.558 | 58.81 | 68.113 | 67.436 | 48.263 | 50.164 | 36.577 | 31.056 | 38.797 | 37.742 | 34.539 | 42.567 | 32.712 |
| Operating Income
| 141.538 | 84.423 | 113.342 | 108.305 | 100.449 | 65.395 | 147.369 | 58.99 | 58.973 | 25.573 | 25.234 | 94.024 | 53.425 | 38.396 | 56.668 | 58.126 | 40.431 | 23.64 | 40.659 | 63.71 | 59.262 | 32.22 | 54.599 |
| Operating Income Ratio
| 0.352 | 0.218 | 0.318 | 0.275 | 0.299 | 0.192 | 0.398 | 0.235 | 0.195 | 0.107 | 0.097 | 0.324 | 0.244 | 0.179 | 0.303 | 0.27 | 0.217 | 0.133 | 0.253 | 0.315 | 0.328 | 0.224 | 0.363 |
| Total Other Income Expenses Net
| -0.002 | -1.612 | -5.132 | 0.138 | -1.341 | -1.116 | -0.279 | -0.023 | -0.229 | 0.004 | -0.125 | -0.355 | -0.048 | -0.161 | -1.085 | -0.106 | -0.257 | 0.06 | -0.102 | -1.095 | -0.396 | 37.275 | -1.673 |
| Income Before Tax
| 141.536 | 82.81 | 108.21 | 117.263 | 99.108 | 64.279 | 147.09 | 58.966 | 58.745 | 25.577 | 68.13 | 93.669 | 53.377 | 38.235 | 55.583 | 58.02 | 40.174 | 23.7 | 40.557 | 62.616 | 58.866 | 69.495 | 52.927 |
| Income Before Tax Ratio
| 0.352 | 0.214 | 0.304 | 0.298 | 0.295 | 0.189 | 0.398 | 0.235 | 0.194 | 0.107 | 0.262 | 0.323 | 0.244 | 0.178 | 0.297 | 0.269 | 0.216 | 0.133 | 0.252 | 0.31 | 0.326 | 0.482 | 0.352 |
| Income Tax Expense
| 22.118 | 11.813 | 13.007 | 10.856 | 16.924 | 7.938 | 11.21 | 7.828 | 13.034 | 3.047 | -1.376 | 18.029 | 12.841 | 3.059 | 5.454 | 7.616 | 7.601 | 6.678 | 3.415 | 9.56 | 8.859 | 3.239 | 5.089 |
| Net Income
| 119.418 | 70.997 | 95.203 | 106.408 | 82.184 | 56.873 | 136.65 | 50.019 | 45.878 | 24.501 | 69.656 | 75.886 | 40.853 | 35.198 | 50.539 | 50.404 | 32.573 | 17.022 | 37.142 | 53.055 | 50.008 | 66.256 | 47.838 |
| Net Income Ratio
| 0.297 | 0.183 | 0.267 | 0.27 | 0.245 | 0.167 | 0.369 | 0.2 | 0.152 | 0.102 | 0.268 | 0.262 | 0.187 | 0.164 | 0.27 | 0.234 | 0.175 | 0.096 | 0.231 | 0.263 | 0.277 | 0.46 | 0.318 |
| EPS
| 0.3 | 0.178 | 0.24 | 0.26 | 0.2 | 0.47 | 0.34 | 0.12 | 0.11 | 0.061 | 0.17 | 0.19 | 0.1 | 0.09 | 0.12 | 0.12 | 0.08 | 0.046 | 0.1 | 0.15 | 0.14 | 0.18 | 0.13 |
| EPS Diluted
| 0.3 | 0.178 | 0.24 | 0.26 | 0.2 | 0.47 | 0.34 | 0.12 | 0.11 | 0.061 | 0.17 | 0.19 | 0.1 | 0.09 | 0.12 | 0.12 | 0.08 | 0.046 | 0.1 | 0.15 | 0.14 | 0.18 | 0.13 |
| EBITDA
| 149.69 | 92.407 | 113.378 | 139.897 | 121.91 | 85.143 | 168.425 | 79.55 | 79.127 | 53.543 | 85.87 | 111.328 | 71.233 | 54.778 | 71.482 | 70.222 | 52.377 | 34.348 | 45.411 | 73.197 | 58.192 | 39.788 | 52.927 |
| EBITDA Ratio
| 0.372 | 0.239 | 0.319 | 0.355 | 0.363 | 0.25 | 0.455 | 0.318 | 0.262 | 0.224 | 0.33 | 0.384 | 0.326 | 0.256 | 0.382 | 0.326 | 0.281 | 0.193 | 0.282 | 0.362 | 0.322 | 0.276 | 0.352 |